Antibody-Drug Conjugates in Breast Cancer: Therapeutic-Window Engineering, Tumor Heterogeneity, and Immunotherapy Combinations
Three principles emerge: ADC efficacy is a systems property; strategies that broaden tumor coverage may also increase normal-tissue exposure; and successful combinations require platform-specific rather than class-wide rationale.